Viatris Inc.
VTRS
Classement en actions
#1103
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its... Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Prix de l'action
$18.25
Dernière synchronisation: 2026-10-19
Capitalisation boursière
$20.96B
Changement (1 jour)
-2.20%
Changement (1 an)
76.96%
Pays
US
Échange Viatris Inc. (VTRS)
Catégorie
Healthcare
Historique du rendement du dividende pour Viatris Inc. (VTRS)
Le rendement du dividende (TTM) de Viatris Inc. (symbole boursier : VTRS) au 2023-12-31 est : 4.43%
Rendement moyen du dividende sur les 5 dernières années : 3.01%
Rendement moyen du dividende sur les 5 dernières années : 3.01%
Historique du rendement du dividende de Viatris Inc. (VTRS) de 2004 à 2026
Rendement du dividende à la fin de chaque année (TTM)
| Année | Rendement du dividende | Changez |
|---|---|---|
| 2026 (TTM) | 2.75% | -28.94% |
| 2024 | 3.87% | -12.64% |
| 2023 | 4.43% | 2.78% |
| 2022 | 4.31% | 76.64% |
| 2021 | 2.44% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | -100.00% |
| 2010 | 2.03% | -17.81% |
| 2009 | 2.47% | -45.95% |
| 2008 | 4.57% | 457.32% |
| 2007 | 0.82% | -11.83% |
| 2006 | 0.93% | 36.76% |
| 2005 | 0.68% | 58.14% |
| 2004 | 0.43% | 0.00% |
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
| Entreprise | Rendement du dividende | Pays |
|---|---|---|
| 0.00% |
DE
|
|
| 0.00% |
DE
|
|
| 0.00% |
JP
|
|
| 0.00% |
CH
|
|
| 0.91% |
IN
|
